Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frey

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Nature Communications|July 26, 2024
Genome of the early spider-orchid Ophrys sphegodes provides insights into sexual deception and pollinator adaptationAlessia Russo, Mattia Alessandrini, Moaine El Baidouri, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Pediatrics|December 28, 2018
Mupirocin for <i>Staphylococcus aureus</i> Decolonization of Infants in Neonatal Intensive Care UnitsKaren L Kotloff, Debbie-Ann T Shirley, C Buddy Creech, et al.
JAMA|July 22, 2015
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical TrialLisa A Jackson, James D Campbell, Sharon E Frey, et al.
The Journal of Infectious Diseases|July 19, 2023
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical TrialHana M El Sahly, Inci Yildirim, Sharon E Frey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody ResponsesKathleen M Neuzil, Evan J Anderson, Robert W Frenck, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
MMWR. Morbidity and Mortality Weekly Report|February 24, 2022
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021Jason H Malenfant, Allison Joyce, Mary J Choi, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Nature Communications|July 26, 2024
Genome of the early spider-orchid Ophrys sphegodes provides insights into sexual deception and pollinator adaptationAlessia Russo, Mattia Alessandrini, Moaine El Baidouri, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Pediatrics|December 28, 2018
Mupirocin for <i>Staphylococcus aureus</i> Decolonization of Infants in Neonatal Intensive Care UnitsKaren L Kotloff, Debbie-Ann T Shirley, C Buddy Creech, et al.
JAMA|July 22, 2015
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical TrialLisa A Jackson, James D Campbell, Sharon E Frey, et al.
The Journal of Infectious Diseases|July 19, 2023
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical TrialHana M El Sahly, Inci Yildirim, Sharon E Frey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody ResponsesKathleen M Neuzil, Evan J Anderson, Robert W Frenck, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
MMWR. Morbidity and Mortality Weekly Report|February 24, 2022
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021Jason H Malenfant, Allison Joyce, Mary J Choi, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Pageof 37